Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2022 - 05 - 17 save search
Consolidated Water Announces Agreement to Construct Wastewater Treatment Plant in Arizona
Published: 2022-05-17 (Crawled : 21:00) - globenewswire.com
CWCO | $24.71 1.9% 42K
|
Utilities
|
| O: 0.6%
H: 5.36%
C: 2.3%
water treatment
AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia
Published: 2022-05-17 (Crawled : 18:00) - biospace.com/
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: 0.0%
avb-101 treatment dementia preclinical pre-clinical
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada’s AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in Adults
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
ajovy treatment drug growing migraine
Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
JSPR | $22.49 -0.13% 44K
|
|
| O: 0.34%
H: 11.74%
C: -0.34%
jsp191 treatment anemia therapeutics
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.5%
H: 2.01%
C: 1.79%
hzn-7734 treatment trial therapeutics enroll phase 2
Global Compressed Air Treatment Equipment Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
Published: 2022-05-17 (Crawled : 15:20) - prnewswire.com
ATLCY | $14.1 17K
|
Manufacturing
|
| O: 7.68%
H: 5.25%
C: 2.46%
ATLKY | $16.19 1M
|
Manufacturing
|
| O: 2.36%
H: 3.07%
C: 2.02%
PH | News | $548.565 1.64% 130K
|
Producer Manufacturing
|
| O: 2.5%
H: 0.82%
C: 0.15%
IR | $90.41 2.01% 660K
|
Producer Manufacturing
|
| O: 2.42%
H: 0.92%
C: 0.81%
treatment air market
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Published: 2022-05-17 (Crawled : 15:20) - globenewswire.com
SRNE | $0.015 140K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
treatment license trial cancer enroll antibody
Deadly Venom is Being Turned into Life-Saving Medical Treatments
Published: 2022-05-17 (Crawled : 14:20) - biospace.com/
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 1.5%
H: 0.64%
C: 0.19%
treatment
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
Published: 2022-05-17 (Crawled : 13:20) - biospace.com/
ALZN | $0.7194 5.02% 17K
|
Professional, Scientific, and T...
|
| O: 0.76%
H: 6.68%
C: 6.44%
al001 treatment submission major depressive disorder
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
Published: 2022-05-17 (Crawled : 12:20) - biospace.com/
TEVA | $12.955 0.58% 4.6M
|
Health Technology
|
| O: 4.77%
H: 4.8%
C: 3.32%
proair treatment potential
NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution
Published: 2022-05-17 (Crawled : 12:20) - biospace.com/
NBSE | $0.42 20K
|
Health Technology
|
| O: 5.26%
H: 7.0%
C: 3.0%
treatment preclinical program distribution pre-clinical
RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies
Published: 2022-05-17 (Crawled : 07:00) - prnewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 1.5%
H: 0.64%
C: 0.19%
treatment antibody disease
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
Published: 2022-05-17 (Crawled : 07:00) - 4dpharmaplc.com
LBPS | $1.65 -0.61%
|
Manufacturing
|
| O: 16.93%
H: 0.0%
C: -8.2%
dp0004 treatment pharma conference trial international
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.81 29.29% 2.8M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
PALI | $6.29 27.59% 22M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.